IDH1 and central nervous system cancer: While this decrease in D-2HG supported that the mutant IDH1 enzyme was being inhibited with AGI-5198 treatment in our chondrosarcoma cell lines, the next question was if we could demonstrate corresponding anti-tumor activity with the compound, similarly to the results seen in gliomas.